Statin myopathy: Significant problem with minimal awareness by clinicians and no emphasis by clinical investigators

Angiology

Volumn 62, Issue 5, 2011, Pages 415-421

  Whayne Jr , Thomas F ^a  

^a UNIVERSITY OF KENTUCKY   (United States)

Author keywords

cardiovascular risk; cholesterol; myopathy; rhabdomyolysis; statins

Indexed keywords

ANTIRETROVIRUS AGENT; ATORVASTATIN; CERIVASTATIN; CREATINE KINASE; CYCLOSPORIN; EZETIMIBE; FLUINDOSTATIN; GEMFIBROZIL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MACROLIDE; MEVINOLIN; PITAVASTATIN; PRAVASTATIN; ROSUVASTATIN; SIMVASTATIN; STATIN; STEROL REGULATORY ELEMENT BINDING PROTEIN; TRIACYLGLYCEROL; UBIDECARENONE;

ABDOMINAL AORTA ANEURYSM; ACUTE CORONARY SYNDROME; ADD ON THERAPY; ALLELE; ARTICLE; AWARENESS; CARDIOVASCULAR RISK; CAROTID ARTERY DISEASE; CAROTID ARTERY OBSTRUCTION; CELL MEMBRANE; CHOLESTEROL BLOOD LEVEL; CHOLESTEROL SYNTHESIS; DEPLETION; DIABETES MELLITUS; DISEASE ASSOCIATION; DNA POLYMORPHISM; DRUG EXPOSURE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENZYME ACTIVITY; GENETIC ASSOCIATION; HEMATURIA; HIGH RISK PATIENT; HOSPITAL READMISSION; HUMAN; HYPOTHYROIDISM; INCIDENCE; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; KIDNEY INJURY; LIMB WEAKNESS; LIPID ANALYSIS; LIVER DYSFUNCTION; META ANALYSIS (TOPIC); MUSCLE WEAKNESS; MYALGIA; MYOGLOBINURIA; MYOPATHY; MYOSITIS; PARKINSON DISEASE; PERIPHERAL OCCLUSIVE ARTERY DISEASE; RANDOMIZED CONTROLLED TRIAL (TOPIC); RHABDOMYOLYSIS; RISK REDUCTION; SINGLE NUCLEOTIDE POLYMORPHISM; STATIN MYOPATHY; SWELLING;

CARDIOVASCULAR DISEASES; CHOLESTEROL, LDL; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MUSCULAR DISEASES;

EID: 79957437683     PISSN: 00033197     EISSN: 19401574     Source Type: Journal    
DOI: 10.1177/0003319710395560     Document Type: Article

References (48)

1. Silva MA, Swanson AC, Gandhi PJ, Tataronis GR Statin-related adverse events: a meta-analysis. Clin Ther. 2006 ; 28 (1). 26-35. (Pubitemid 43254987)
2. Phillips PS, Haas RH, Bannykh S., et al. Statin-associated myopathy with normal creatine kinase levels. Ann Intern Med. 2002 ; 137 (7). 581-585.
3. Joy TR, Hegele RA Narrative review: statin-related myopathy. Ann Intern Med. 2009 ; 150 (12). 858-868.
4. Nichols GA, Koro CE Does statin therapy initiation increase the risk for myopathy? An observational study of 32,225 diabetic and nondiabetic patients. Clin Ther. 2007 ; 29 (8). 1761-1770. (Pubitemid 47494553)
5. Bruckert E., Hayem G., Dejager S., Yau C., Begaud B. Mild to moderate muscular symptoms with high-dosage statin therapy in hyperlipidemic patients-the PRIMO study. Cardiovasc Drugs Ther. 2005 ; 19 (6). 403-414. (Pubitemid 43228152)
6. Harper CR, Jacobson TA The broad spectrum of statin myopathy: from myalgia to rhabdomyolysis. Curr Opin Lipidol. 2007 ; 18 (4). 401-408. (Pubitemid 47051918)
7. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994 ; 344 (8934). 1383-1389.
8. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. N Engl J Med. 1998 ; 339 (19). 1349-1357.
9. Sacks FM, Pfeffer MA, Moye LA, et al. The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators. N Engl J Med. 1996 ; 335 (14). 1001-1009. (Pubitemid 26338729)
10. Shepherd J., Cobbe SM, Ford I., et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. West of Scotland Coronary Prevention Study Group. N Engl J Med. 1995 ; 333 (20). 1301-1307.
11. Nissen SE, Tuzcu EM, Schoenhagen P., et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA. 2004 ; 291 (9). 1071-1080. (Pubitemid 38541684)
12. Cannon CP, Braunwald E., McCabe CH, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004 ; 350 (15). 1495-1504. (Pubitemid 38477774)
13. Nissen SE, Nicholls SJ, Sipahi I., et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA. 2006 ; 295 (13). 1556-1565.
14. Silva M., Matthews ML, Jarvis C., et al. Meta-analysis of drug-induced adverse events associated with intensive-dose statin therapy. Clin Ther. 2007 ; 29 (2). 253-260. (Pubitemid 46661859)
15. Josan K., Majumdar SR, McAlister FA The efficacy and safety of intensive statin therapy: a meta-analysis of randomized trials. CMAJ. 2008 ; 178 (5). 576-584. (Pubitemid 351414005)
16. Newman C., Tsai J., Szarek M., Luo D., Gibson E. Comparative safety of atorvastatin 80 mg versus 10 mg derived from analysis of 49 completed trials in 14,236 patients. Am J Cardiol. 2006 ; 97 (1). 61-67. (Pubitemid 41828124)
17. Thompson PD, Clarkson P., Karas RH Statin-associated myopathy. JAMA. 2003 ; 289 (13). 1681-1690. (Pubitemid 37430274)
18. Wortmann RL Dose-related statin myopathy: is it an issue ? Cleve Clin J Med. 2005 ; 72 (9). 751-753, 756.
19. Link E., Parish S., Armitage J., et al. SLCO1B1 variants and statin-induced myopathy-a genomewide study. N Engl J Med. 2008 ; 359 (8). 789-799.
20. Arnaboldi L., Corsini A. Do structural differences in statins correlate with clinical efficacy ? Curr Opin Lipidol. 21 (4). 298-304.
21. Bolego C., Baetta R., Bellosta S., Corsini A., Paoletti R. Safety considerations for statins. Curr Opin Lipidol. 2002 ; 13 (6). 637-644. (Pubitemid 36009203)
22. Bosch X., Poch E., Grau JM Rhabdomyolysis and acute kidney injury. N Engl J Med. 2009 ; 361 (1). 62-72.
23. Melli G., Chaudhry V., Cornblath DR Rhabdomyolysis: an evaluation of 475 hospitalized patients. Medicine (Baltimore). 2005 ; 84 (6). 377-385. (Pubitemid 41668936)
24. Veenstra J., Smit WM, Krediet RT, Arisz L. Relationship between elevated creatine phosphokinase and the clinical spectrum of rhabdomyolysis. Nephrol Dial Transplant. 1994 ; 9 (6). 637-641. (Pubitemid 24192949)
25. Staffa JA, Chang J., Green L. Cerivastatin and reports of fatal rhabdomyolysis. N Engl J Med. 2002 ; 346 (7). 539-540.
26. Wensel TM, Waldrop BA, Wensel B. Pitavastatin: a new HMG-CoA reductase inhibitor. Ann Pharmacother. 2010 ; 44 (3). 507-514.
27. Brewer HB, Jr. Benefit-risk assessment of Rosuvastatin 10 to 40 milligrams. Am J Cardiol. 2003 ; 92 (4B). 23K - 29K.
28. Sukhija R., Aronow WS, Yalamanchili K., Peterson SJ, Frishman WH, Babu S. Association of ankle-brachial index with severity of angiographic coronary artery disease in patients with peripheral arterial disease and coronary artery disease. Cardiology. 2005 ; 103 (3). 158-160. (Pubitemid 41094865)
29. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004 ; 110 (2). 227-239. (Pubitemid 38924592)
30. Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) final report. Circulation. 2002 ; 106 (25). 3143-3421.
31. Whayne TF, Jr. A viewpoint on statin effects-benefits and problems. Int J Angiol. 2008 ; 17 (1). 178-180.
32. Lexchin J. Pricing of multiple dosage prescription medications: an analysis of the Ontario Drug Benefit Formulary. Health Policy. 2009 ; 91 (2). 142-147.
33. Schwartz GG, Olsson AG, Ezekowitz MD, et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001 ; 285 (13). 1711-1718. (Pubitemid 32259905)
34. Jones PH, Davidson MH, Stein EA, et al. Comparison of the efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR* Trial). Am J Cardiol. 2003 ; 92 (2). 152-160. (Pubitemid 36835963)
35. LaRosa JC, Grundy SM, Waters DD, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N Engl J Med. 2005 ; 352 (14). 1425-1435. (Pubitemid 40471450)
36. Gagne C., Bays HE, Weiss SR, et al. Efficacy and safety of ezetimibe added to ongoing statin therapy for treatment of patients with primary hypercholesterolemia. Am J Cardiol. 2002 ; 90 (10). 1084-1091. (Pubitemid 35339435)
37. Athyros VG, Tziomalos K., Kakafika AI, Koumaras H., Karagiannis A., Mikhailidis DP Effectiveness of ezetimibe alone or in combination with twice a week Atorvastatin (10 mg) for statin intolerant high-risk patients. Am J Cardiol. 2008 ; 101 (4). 483-485. (Pubitemid 351199439)
38. Gazi IF, Daskalopoulou SS, Nair DR, Mikhailidis DP Effect of ezetimibe in patients who cannot tolerate statins or cannot get to the low density lipoprotein cholesterol target despite taking a statin. Curr Med Res Opin. 2007 ; 23 (9). 2183-2192. (Pubitemid 350246604)
39. Tziomalos K., Athyros VG, Mikhailidis DP Statin discontinuation: an underestimated risk? Curr Med Res Opin. 2008.
40. Daskalopoulou SS, Delaney JA, Filion KB, Brophy JM, Mayo NE, Suissa S. Discontinuation of statin therapy following an acute myocardial infarction: a population-based study. Eur Heart J. 2008 ; 29 (17). 2083-2091.
41. Stancu C., Sima A. Statins: mechanism of action and effects. J Cell Mol Med. 2001 ; 5 (4). 378-387.
42. Gadarla M., Kearns AK, Thompson PD Efficacy of rosuvastatin (5 mg and 10 mg) twice a week in patients intolerant to daily statins. Am J Cardiol. 2008 ; 101 (12). 1747-1748.
43. Crane FL Biochemical functions of coenzyme Q10. J Am Coll Nutr. 2001 ; 20 (6). 591-598.
44. Ellis CJ, Scott R. Statins and coenzyme Q10. Lancet. 2003 ; 361 (9363). 1134-1135.
45. Bonakdar RA, Guarneri E. Coenzyme Q10. Am Fam Physician. 2005 ; 72 (6). 1065-1070. (Pubitemid 43093261)
46. Davidson MH, Armani A., McKenney JM, Jacobson TA Safety considerations with fibrate therapy. Am J Cardiol. 2007 ; 99 (6A). 3C - 18C.
47. Chang JT, Staffa JA, Parks M., Green L. Rhabdomyolysis with HMG-CoA reductase inhibitors and gemfibrozil combination therapy. Pharmacoepidemiol Drug Saf. 2004 ; 13 (7). 417-426. (Pubitemid 38996852)
48. Prueksaritanont T., Zhao JJ, Ma B., et al. Mechanistic studies on metabolic interactions between gemfibrozil and statins. J Pharmacol Exp Ther. 2002 ; 301 (3). 1042-1051. (Pubitemid 34595097)